Nkarta: A Look Into Q1 Results And Upcoming Catalysts [Seeking Alpha]
Nkarta, Inc. (NKTX)
Company Research
Source: Seeking Alpha
The company's stock has been trending down, but there are signs of recovery, with a 6.4% increase in share price. The success of Nkarta's lead program, NKX019, in clinical trials will be crucial for the company's future and potential revenue generation. Thesis Nkarta, Inc. NASDAQ: NKTX ) has recently raised $240.1 million via an underwritten offering of common stock shares and warrants, thereby strengthening its cash position, $446.79 million by March 2024, and extending its cash runway to 2027. Despite the shareholder dilution, the cash runway extension might provide financial stability for completing clinical trials and for bringing its lead therapeutic candidates to the market. In this sense, the company is expecting to make public results from the clinical trials associated with NKX019 in Lupus nephritis (LN) as well as non-Hodgkin Lymphoma (NHL) by mid-2024. In my opinion, investors should be paying attention to those results as it will be very informative in terms of th
Show less
Read more
Impact Snapshot
Event Time:
NKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTX alerts
High impacting Nkarta, Inc. news events
Weekly update
A roundup of the hottest topics
NKTX
News
- Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of DirectorsGlobeNewswire
- Nkarta: Finally An Attractive Valuation [Seeking Alpha]Seeking Alpha
- enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Nkarta, Inc. (NASDAQ: NKTX) had its price target lowered by analysts at Needham & Company LLC from $15.00 to $13.00. They now have a "buy" rating on the stock.MarketBeat
NKTX
Earnings
- 5/9/24 - Miss
NKTX
Sec Filings
- 6/20/24 - Form 4
- 6/20/24 - Form 4
- 6/20/24 - Form 4
- NKTX's page on the SEC website